key: cord-1012099-mrf7z2ql
authors: Nasonov, E.; Samsonov, M.
title: The role of Interleukin 6 inhibitors in therapy of severe COVID-19
date: 2020-08-28
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2020.110698
sha: 678cc68e3b5b43fc9d1c60769ddda39da6a912a2
doc_id: 1012099
cord_uid: mrf7z2ql

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases or treatment of malignancies; it may also appear during the progression of COVID-19. CSS is caused by dysregulation of the synthesis of cytokines, including pro-inflammatory, regulatory, and anti-inflammatory cytokines and chemokines, leading to pathologic activation of innate and adaptive (Th1 and Th17 mediated) immunity. Interleukin-6 (IL-6) plays an important role in the pathogenesis of CSS. The significant role of IL-6 in pathogenesis of COVID-19 was confirmed in a range of studies, which showed that the plasma concentration of IL-6 was increased in patients with severe COVID-19. Currently, IL-6 inhibitor therapeutics are not yet approved for the treatment of COVID-19; however, these medicines, including tocilizumab (TCZ) are used off-label for the treatment of patients with severe COVID-19, including life-threatening conditions. The role of IL-6 in the pathogenesis of CSS during COVID-19 is important however, a number of related issues are not yet clear. These issues include the indications for treatment with IL-6 inhibitors, as well as the estimation of risk associated with the disease, outcomes, treatment options, and adverse drug reactions. The development of personalized immunomodulatory therapy, with respect to the role of cytokines in pathogenesis, requires the studies that aimed to find other relevant therapeutic targets for the treatment of CSS in patients with COVID-19. These therapeutic targets include inhibition of IL-1, IL-6, TNFα, GM-CSF, IFNγ, IL-17, IL-18, and also activation of the complement system. The challenge of CSS in patients with COVID-19 is identifying the correct scientific targets and developing clinical trials aimed to evaluate the pathogenesis and treat immune-mediated inflammatory diseases (IMIDs). Hopefully, the significant efforts of scientists and physicians across the globe will improve the prognosis in COVID-19 patients and provide useful information on IMIDs required to support the struggle for treating potential viral outbreaks, and treatment of well-known IMIDs.

The role of interleukin 6 inhibitors in therapy of severe COVID-19 Nassonov E, Samsonov M RM, Resident macrophages; INF, interferons; NK, natural killers; G-CSF, granulocyte colonystimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor, TNFα, tumor necrosis factor alpha; IP-10, interferon (IFN)γ-induced protein 10; MIP1α, macrophage inflammatory protein; CCL2, CCL7, CXCL9, CXCL10, chemokines.

The 2019 Coronavirus Disease and associated global pandemic [1, 2] have drawn attention to new clinical and fundamental issues in the immunopathology of human diseases.

The unique experience gained in the treatment of rheumatology patients and of studying the pathogenetic mechanisms and pharmacotherapy of immunoinflammatory rheumatic diseases (IMRD) is of great importance for deciphering the nature of the pathological processes underlying severe, potentially fatal complications of COVID-19 [3, 4] In COVID-19 patients, the hyperimmune response, rather than the action of the virus itself, contributes to the pathogenesis of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndromes [5] . Repurposing certain widely used immunomodulators [6] , such as glucocorticoids (GC), disease-modifying anti-rheumatic drugs (DMARDs), and biologic drugs based on recombinant fusion proteins and targeted DMARDs [3, 4, 7] is a logical first step when faced with a new disease that caused a hyperimmune response.

The pathogenetic mechanisms of COVID-19 are summarized in a series of reviews [8, 9] .

Relevant to remind that SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2) is the established etiological factor of COVID-19, infecting primarily type II pneumocytes and other cells expressing angiotensin-converting enzyme (ACE) 2 protein, which is as a receptor and entry point for the virus. Replication of SARS-CoV-2 produces a cytopathic effect on target cells, causing their pyroptosis (pro-inflammatory form of programmed cell death --apoptosis), therefore inducing synthesis of interleukin-1 (IL-1) and other proinflammatory cytokines by myeloid cells as part of innate immunity activation process. Noteworthy, along with the activation of immune cells, SARS-CoV-2 expresses proteins that inhibit the synthesis of type I Interferon (IFN) (IFNα and IFNß), thereby weakening antiviral immune responses and providing an optimal environment for rapid replication of the virus. Increasing of the viral load and enhancing viral cytopathic effects, results in the rapid progression of the immunoinflammatory process [10, 11] leading to CSS [12] [13] [14] [15] [16] . Clinical manifestations of CSS include primary and secondary hemophagocytic lymphohistiocytosis [17] , macrophage activation syndrome [18] , and cytokine release syndrome as a complication of therapy with CAR T-cells (Chimeric Antigen Receptor T-Cells) [19] .

The pathogenetic origin of CSS is associated with the dysregulated synthesis of a wide range of cytokines (pro-inflammatory, immunoregulatory, and anti-inflammatory) and chemokines, reflecting the pathological activation of innate and acquired (Th1 and Th17) immunity. These include IL-1, IL-2, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF)-α, interferon (IFN)γ-induced protein 10 IL-6 seems to play a crucial role among all cytokines involved in the pathogenesis of CSS in IMIDs [32] and COVID-19 [15, 33, 34] . Introduction of monoclonal antibodies (mAbs) inhibiting this cytokine receptors with medicines such as Tocilizumab and Sarilumab, into clinical practice has been a major achievement in treating IMIDs [35, 36] , and in recent years -in the management of critically ill patients with CSS [32,37], including COVID-19 [33, 38] . Data related to biological effects and molecular MOA of IL-6 are understood and are summarized in a number of published reviews [39, 40] . IL-6 is known as a multifunctional (pleiotropic) cytokine, synthesized by immune and stromal cells in response to activation of toll-like receptors mediated by "molecular patterns" associated with pathogens and damage (pathogen-associated molecular patterns and damageassociated molecular patterns) ( Figure 2 ).

The biological activity of IL-6 is determined by its potential to activate target genes that regulate cell differentiation, survival, proliferation, and apoptosis. IL6 functions as an autocrine, paracrine, and "hormone-like" regulator of various normal and pathological biological processes associated with local and systemic inflammation, metabolism, and tumorigenesis. Its pleiotropic properties are determined by a unique signaling system that includes IL-6 receptors (R) and J o u r n a l P r e -p r o o f downstream signaling molecules. IL-6R consists of 2 chains: IL6-binding chain (IL6-Rα), and transmembrane protein gp130 (130 kDa glycoprotein) (IL6-Rß), which is a signal receptor. MIl-6Rα is expressed only in particular types of cells (macrophages, neutrophils, CD4 T cells, hepatocytes, podocytes, megakaryocytes, and specialized intestinal epithelial cells); while gp130 (IL6-Rß) is present in almost all cells of the human body. Initiation of the IL6-induced signaling cascade begins after binding of the IL-6 andIL-6-R complex to gp130, which, when dimerized, leads to activation of Janus kinases 1 and 2, via phosphorylation of tyrosine residues of the gp130 cytoplasmic site. Most human cells do not express mIl6-Rα, and therefore are resistant to the biological effects of IL6. However, the bloodstream and tissues also contain a soluble (s) form of IL6-Rα, which is formed by proteolytic cleavage mediated by Zn2+ metalloprotease ADAM (a Disintegrin and Metalloproteinase domain) 10 and 17, and, to a lesser extent, by "alternative splicing" of messenger RNA. SIl6-Rα protects IL-6 from enzymatic cleavage, and therefore, prolongs its circulation in the blood and, most importantly, in tandem with IL6, sIL-6Rα can bind to gp130, therefore activating many cell types that do not express mIL-6Rα. This process is called "trans-signaling", while cell activation mediated by the interaction of IL6 with mIl6-R is defined as cis-signaling. Hypothetically pathogenic effects of IL-6 are mostly determined by transsignaling rather than cis-signaling. At the same time, "classical" (cis) signaling is also involved in the induction of acute-phase response, the production of pathogenic Th17 and Th22 cells, and suppression of T regulatory cells. Therefore, trans and cis-signaling provide a multidirectional contribution to the development of the immunopathological process in the course of disease progression. "Trans-presentation" as a new mechanism of IL-6 signaling has been described recently when IL6 binds to IL-6Rα on the membrane of specialized dendritic cells and is "presented" to the gp130 homodimer, expressed on the surface of cognate T cells. This mechanism is believed to play a major role in actualizing IL-6 potential to induce differentiation of pathogenic subpopulation of Th17 cells [41] .

(p=0.001) and pyrexia (p=0.001) [55] . Other studies have shown that increasing IL-6 concentrations are associated with the progression of ARDS (p=0.03) and the risk of death [46] .

According to another meta-analysis [56] (9 studies, 1426 patients), the average IL6 concentration in patients with severe COVID-19 was significantly higher than in non-severe cases (mean difference was 38.6 pg/ml; p<0.001). Meta-regression indicates that increased IL-6 concentrations were significantly associated with an increase in mortality (p=0.03). The risk of developing severe COVID-19 increases at IL-6 concentrations >55 pg/ml, and the risk of death at values >80 pg/ml. In critically ill COVID-19 patients, increased serum IL-6 concentrations correlate with the extent of inflammatory pulmonary involvement (>50%) following CT data, and a significant drop in CD4+ and CD8+ counts [49] . Data from T Herold et al. [54] shows that increased IL-6 concentration is significantly associated with the need for ventilatory support and the predicted development of respiratory failure (IL-6 > 80 pg/ml, AUC=0.98). While, generally, SARS-CoV-2 viral load does not correlate with the severity of COVID-19 [67] , SARS-CoV-2 RNA is usually detected in the serum of critically ill COVID-19 patients (RNAemia) in combination with a marked increase in IL6 levels [57] . This is consistent with the concept of "viral sepsis" as the leading cause of CSS in COVID-19 [58] .

As already noted, mAbs blocking IL-6 binding to receptors (Tocilizumab, Sarilumab) or IL-6 from 152±52 to 283,73±115,8 on day 7 and to 302,2±126 on day 14 of the study (p<0.05). The mortality rate was 11%; fatal outcomes were associated with higher levels of D-dimer rather than IL-6. Initiation of therapy with TCZ within the first 6 days of hospitalization was associated with increased survival rate: the hazard ratio (HR) was 2.2; 95% CI: 1,3-6,7; p<0.05.

A Retrospective study of Alattar et al [62] showed in 25 patients with COVID-19 the treatment with TCZ was associated with normalization of body temperature, reduced CRP levels (р=0.0001), improvements on CT in 44% and in 68% of patients on day 7 and day 14 respectively.

The number of patients who needed mechanical ventilation was reduced from 84% to 60% on day 7 and to 28% on day 16 (р=0.001). During the follow-up period, 9 (36%) patients were discharged from the hospital; 3 patients died.

Uysal et al [63] reported improvements in 10 of 12 COVID-19 patients after infusions with TCZ. These improvements include normalization of oxygen saturation levels (from 87.58±3.12% to 94.42±1%), body temperature, and CRP levels. All patients were discharged from hospitals within 18 days.

Gorgolas et al. [64] analyzed the outcomes of therapy with TCZ for 186 COVID-19 patients;

169 (91%) patients received a single infusion of TCZ, 16 patients received 2 infusions and 1 patient received 3 infusions. The majority of these patients (95.7%) were treated with methylprednisolone (250 mg once daily during the three days before infusion with TCZ). On day 15, fatal outcomes were reported for 36 patients; these outcomes were associated with older age (P<0.001), comorbidities (89% vs 63%, р=0.003), high IL-6 levels (р<0.001), high CRP levels (p<0.009), lymphopenia (р=0.001), or increased concentration of D-dimer (р=0.027).

Early initiation of therapy with TCZ (patients with FiO2≤0.5%) was associated with better outcomes (assessed by the need for mechanical ventilation and mortality rates), as compared with later initiation of TCZ-based therapy patients with FiO2 >0.5%, (13% vs 37%, p<0.001).

Severe adverse drug reactions related to TCZ were noted in 11 (59%) patients; infections (as a complication of the main disease) were reported in 13 (6.3%) patients. According to Marfella et al. [65] , during treatment with TCZ in COVID-19 patients, hyperglycemia is associated with higher risk as compared to the patients with normal blood glucose levels (P<0.009). in the control group, these values were 5 days (p = 0.039) and 10 days (p = 0.11), respectively.

The incidence of infectious complications was similar in both groups: 18% and 22%, respectively.

Petrac et al. [87] presented the results of a retrospective analysis of a multicenter study, hours. There was no correlation between the TCZ dose and changes in these parameters (p = 0.080 and p = 0.10, respectively). Mortality rate within 28 days was 15.6%. A total of 5 (15.5%) patients had clinical or bacteriological signs of infection. Any effect of TCZ on the production of antibodies to SARS-CoV-2 was not observed.

Two meta-analyses [104, 105] summarized the information from most of the studies mentioned above. In these meta-analyses, the efficacy of TCZ was assessed in patients with COVID-19.

A meta-analysis of Kaye et al [103] included 9 studies with a control group [77, 82, 83, 89, 94, [97] [98] ]; a total of 618 patients received TCZ and 1057 patients were in control groups. This meta-J o u r n a l P r e -p r o o f analysis showed that the mortality rate was 26.1% in the TCZ groups and 41.5% in the control groups (odds ratio 0.492, 95% CI 0.326-0.713, p <0.001).

In non-controlled studies (n = 803 patients) [59-63, 66-68, 71, 72] , mortality rate in patients treated with TCZ was 13.5%.

Another meta-analysis of Boregowda et al [105] was based on the results of 13 retrospective In the study of E Della -Torre et al [107] , 28 patients with COVID-19 pneumonia received SAR (400 mg, intravenous), and another 28 patients were in the control group. After 28 days in the SAR group, clinical improvement was observed in 61% of patients, the mortality rate was 7%; similar results were obtained in the control group: 64% and 18%, respectively (p> 0.05). In the SAR group, clinical improvement correlated with PaO2/FiO2 ratio>100 mm Hg and lung impairment <17% on computed tomography. In patients with lung impairment <17% who received SAR, clinical recovery was faster (on average after 10 days) than in patients who received standard therapy (on average after 24 days) (p = 0.01).

In the study of M Benucci et al [108] , lung recovery, estimated by the SpO2/FiO2 ratio, was observed in 7 out of 8 patients with COVID-19 pneumonia who received TCZ treatment. Clinical recovery was associated with an increase in lymphocyte count, reduced IL-6, and CRP levels.

Meanwhile, preliminary results of a multicenter RCT (phase II/III) of SAR, which included 400 COVID-19 patients in severe or critical condition (the need for mechanical ventilation, high-speed nasal flow, and/or hospitalization in the ICU), are disappointing [109] . The phase II interim analysis did not reveal significant differences in the efficacy of therapy with SAR 400 mg IV (n = 145) vs. control group (n = 77) for all analyzed endpoints: mortality rate (23% versus 27%), the need for mechanical ventilation (23% versus 27%), clinical improvement (59% versus 41%), discontinuation of high-speed nasal flow procedures (58% versus 41%), and hospital discharge (53% versus 41%). The only relevant finding was a more pronounced decrease in the concentration of CRP in the SAR group vs. control group (-79% versus -21%).

Preliminary results on the efficacy and safety of SLT have been obtained in 21 patients with COVID-19 complicated by ARDS [110] . In general, the efficacy of therapy can be assessed as satisfactory. All patients showed normalization (within 5-7 days) of CRP levels, 2 out of three patients showed improvement or stabilization of lung function. Nevertheless, 5 patients showed exacerbation of the disease (one patient died), requiring mechanical ventilation.

J o u r n a l P r e -p r o o f

Despite the undoubted efficacy of IL-6 inhibitors in patients with severe COVID-19, the role of these drugs and IL-6 in the pathogenesis of CSS should be further investigated [111] [112] [113] .

In patients with severe COVID-19, the average concentration of IL-6 in the blood serum is significantly lower (in the range from 7 to 627 mg/ml, on average 132.32 ± 278.54 pkg/ml)

[26, [114] [115] [116] [117] than in patients with ARDS caused by other viral infections (578-1618 pg/ml) [118] [119] [120] . Viral pneumonia in COVID-19 is thought to be associated with severe local inflammation rather than systemic hyperimmune response associated with ARDS.

The plasma concentration of IL-6 in patients with CSS as a complication of CAR-T-cell therapy reaches 10,000 pg/ml; that is 1000 times higher than in patients with CSS triggered by COVID-19 [121] .

An increase in IL-6 concentration up to 50 pg/ml is often observed during active inflammationin patients with rheumatoid diseases in the absence of ARDS and other manifestations of cytokine storm [122] [123] [124] [125] . Administration of recombinant human IL-6 to cancer patients at a dose range from 10 μg/kg to 20 μg/ml leads to a pronounced increase in serum IL-6 concentration (>4000 pg/ml), and was not associated with severe lung impairment or multi-organ failure [126] . IL-6

plays an important role in antiviral and antibacterial defense mediatedby the immune system [127] . As a result, treatment with IL-6 inhibitors in patients with rheumatoid arthritis may lead to infectious complications and other ADRs [35,].

In RECOVERY (Randomized Evaluation of COVid-19 thERapY) study, therapy with dexamethasone (6 mg per day for 10 days) was associated with reduced mortality (within 28 days) in patients with COVID-19 (n = 2104) who were on mechanical ventilation (from 40% to 28%; p = 0.0003) or on supplemental oxygen (from 25% to 20%; p = 0.0021), as compared to the control group (n = 4321). In patients who did not receive supplemental oxygen, the superiority of dexamethasone was not demonstrated (p = 0.14) [128] . Thus, the issues of the comparative efficacy of IL-6 and GC, advantages of combination therapy with IL-6 and GC, optimal timing of initiation of treatment with these drugs, and the choice of patients for whom this therapy will be most effective should be further investigated.

Recently, preliminary results of COVACTA clinical trial has been announced. There was no statistical difference between tocilizumab vs placebo arm in severe COVID-19. TCZ didn't meet J o u r n a l P r e -p r o o f Observed data emphasize heterogenecity of cytokine storm immunopathology mechanism in COVID-19. Therefore, GC maybe uniqluy positioned in antiinflammatory control due to inhibiting broader range of cytokines IL-6, IL-1α/β, IL-12, IL-17, IFN-γ, TNF-α (130) .

It should be emphasized that the "Treat to Target" (T2T) strategy has been successfully adapted in rheumatology since long ago; T2T mandates early aggressive therapy (within "window of opportunity") with the most effective drugs to achieve remission of the disease [130] . We damage to major internal organs [135] . There are also reports of Ruxolitinib efficacy in adult patients with secondary HLH [136] [137] [138] and COVID-19 pneumonia [139, 140] . Major concerns with early use of IL-6 and JAK inhibitors in COVID-19 are related to potential immune suppression during ongoing anti-viral immune response [141] , challenging the administration of these agents in the early period of COVID-19 during the viremic phase. However, reported preliminary data suggests that IL-6 itself can maintain the persistence of viruses via different mechanisms, including downregulated expression of perforin and granzyme in natural-killer (NK) cells involved in antiviral immunity [142] .

In the broader context of immunomodulatory "personalized therapy" [143] [144] [145] there is an ongoing intensive search within the concept of cytokine-based disease taxonomy [146, 147] for other adequate therapeutic targets to manage CSS in patients with COVID-19. Apart from IL-6, the relevance of other proinflammatory cytokines inhibition is being extensively explored (or discussed): IL-1β [148, 149] , TNFα [150] , GM-CSF [151] , IL-17 [152] , IL-18 [153] , as well as activation of the complement system [154] .

One among newly emerged pharmacotherapy trends is based on IL-1inhibition. IL-1

inhibitors: Anakinra (a recombinant antagonist of the IL-1 receptor) and Canakinumab (mAb to IL-1β), are very effective in a wide range of autoinflammatory diseases [148] . Anakinra was successfully used in sepsis [155] , HLH [149, 156] , and MAS [157] . Just recently, successful use of Anakinra, as well as IL-6 inhibitors, was reported in patients with severe COVID-19 pneumonia [158] [159] [160] [161] [162] [163] [164] [165] [166] .

GM-CSF, a proinflammatory cytokine synthesized primarily by myeloid cells and involved in differentiation and proliferation of neutrophils, dendritic cells, macrophages, and endothelial cells [167] is considered as a potential therapeutic target for both RA [168] and possibly COVID-19 [169, 170] . GM-CSF signaling is mediated by JAK2 and is potentially blocked by BARI and other JAK inhibitors. A dedicated RCT (BREATH) is planned to evaluate the efficacy and safety of humanized anti-GM-CSF mAbs in patients with severe COVID-19 complicated by ARDS [171] .

The complement system, on the one hand, is an important component of the innate immune response against viral infections, and on the other, it plays an essential role in inflammatory damage to organs and tissues [172] . Massive deposits of activated complement components (C3A) in biopsied lung tissue specimens, increased serum concentrations of C5A

(anaphylatoxin), deposits of C5b-9 (membrane-attacking complex), as well as C4D and serine J o u r n a l P r e -p r o o f protease associated with mannose-associated lectin (mannose lectin-associated serine protease) in skin and lungs microvasculature were detected in COVID-19 patients. Therefore, provided evidence confirms that activated via alternative and lectin pathways complement system operates as a tasked effector mechanism of systemic micro thrombosis (thrombo-inflammation)

in COVID-19 [173] . Preliminary results are indicative efficacy of Eculizumab (humanized mAb, IgG2/4k, blocks the C5A component of the complement and inhibits the production of a membrane-attacking complex) [174] as well as new low-molecular-weight C3A inhibitor of the compstatin family (AMI-101) [175] in patients with COVID-19 complicated by ARDS.

Intravenous immunoglobulin (IVIG) with a wide range of immunomodulatory, antiviral ,and antibacterial effects [176] is also used in COVID-19 patients with severe exacerbations of immuno-mediated diseases and sepsis. A series of studies demonstrated the positive effects of multiple IVIG infusions in severe COVID-19 [177, 178] .

Therefore, the challenge of CSS in COVID-19 has engaged many areas of scientific and clinical research involved in the exploration of immunopathogenic mechanisms and therapeutic approaches to the management of IMIRDs in an unprecedentedly short time. Hopefully, the extraordinary efforts of scientists and physicians around the world will not only improve the prognosis for COVID-19 patients, facilitate the accumulation of valuable knowledge to control successful epidemics of viral infections that humanity may face in the future, but will also contribute to the improvement of current pharmacotherapy of widespread IMIRDs.

This study had no sponsorship. The author is fully responsible for submitting the final version of the manuscript to the press.

The author independently developed the concept of the article and prepared the manuscript.

The author did not receive a fee for the article.

J o u r n a l P r e -p r o o f 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

A new coronavirus associated with human respiratory disease in China

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

COVID-19 revising inflammatory pathways of arthritis

Coronavirus infections and immune responses

Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

The trinity of COVID-19: immunity, inflammation and intervention

Immunology of COVID-19: Current State of the Science

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

SARS-CoV-2: a storm is raging

On the Alert for Cytokine Storm: Immunopathology in COVID-19

Cytokine release syndrome in severe COVID-19

Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes

Adult haemophagocytic syndrome

Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies

Cytokine release syndrome

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Interleukin-6: designing specific therapeutics for a complex cytokine

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells

Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis

The potential role of IL-6 in monitoring severe case of coronavirus disease 2019

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published correction appears in Intensive Care Med

Reduction and functional exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19)

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

SARS-CoV-2 and viral sepsis: observations and hypotheses

Tocilizumab treatment in COVID-19: A single center experience

Effective treatment of severe COVID-19 patients with tocilizumab

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19

Tocilizumab for the treatment of severe coronavirus disease

Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients

Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late. medRxiv 2020.06.13

Negative impact of hyperglycemia on Tocilizumab therapy in

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes

Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

Feasibility of tocilizumab in ICU patients with COVID-19

Early tocilizumab treatment could improve survival among COVID-19 patients

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19

Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study

Temporal clinical and laboratory response to interleukin-6 receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 pneumonia. medRxiv 2020.06.12

Tocilizumab in Covid-19 Interstitial Pneumonia: A Phase II Pilot Study

A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia

Interleukin-6 blockade for severe COVID-19

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study medRxiv 2020.05.14

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms

Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2. medRxiv preprint

Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients

on behalf of Montichiari COVID

Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study

Tocilizumab and steroid treatment in patients with severe Covid-19 pneumonia

Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients -An 13

Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection/ medRxiv 2020.06.05

IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

The Efficacy of IL-6 Inhibitor Tocilizumab in Reducing Severe COVID-19 Mortality: A Systematic Review

Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A and meta-analysis

Sarilumab use in severe SARS-CoV-2 pneumonia

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients

Begin Global Kevzara (Sarilumab) Clinical Trial Program in Patients with Severe COVID-19. Regeneron/Sanofi

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support

Is a "Cytokine Storm" Relevant to COVID-19?

Rethinking interleukin-6 blockade for treatment of COVID-19

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

Potential Role of Antiinterleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy

Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study

Current status of chimeric antigen receptor therapy for haematological malignancies

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis

The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab

Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab

Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosuspatients?

Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study

The Role of Interleukin 6 During Viral Infections

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Immune regulation by glucocorticoids

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

COVID-19: combining antiviral and antiinflammatory treatments

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome

A Precision Medicine Approach to SARS-CoV-2 Pandemic Management

Therapy in COVID-19

Immunomodulation in COVID-19

How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

The IL-1 family of cytokines and receptors in rheumatic diseases

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches

Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies

COVID-19: a case for inhibiting IL-17

Fire behind the fury: IL-18 and MAS

Complement as a target in COVID-19?

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of

Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial

Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis

Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

Interleukin-1 safe and may result in clinical improvement

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

Anakinra for severe forms of COVID-19: a cohort study

Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19

GM-CSF-Dependent Inflammatory Pathways. Front Immunol

Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects

First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease

Temple Treats First Patient in the U.S. in Clinical Trial of Gimsilumab for Patients with COVID-19 and Acute Respiratory Distress Syndrome

Therapeutic targeting of the complement system

Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Update on the use of immunoglobulin in human disease: A review of evidence

Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19

High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease